DEA genes that were down-regulated in basal-like PDOs with prognostic impact in the PanGen patient cohort included SLCO2A1, CEACAM7 and NR5A2. SLCO2A1 encodes a bidirectional prostaglandin transporter PGT and its low expression is associated with worse prognosis in gastric and breast cancers [45, 46]. This evidence concerns the gene NR5A2 and breast cancer.